2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5709 Belantamab mafodotin treatment does not compromise the B-cell maturation antigen (BCMA) target for subsequent BCMA-targeting therapies for multiple myeloma (MM)

Hanny Musa, Francesco Maura, MD2, Marc-Steffen Steffen Raab, MD3, Chanhyung Bae4, Mary Birchler5, Chun-Wa Chung6, Boyenoh Gaye7, Panchali Goswami8, Zeyad Khalaf, PharmD9, Kelly McGrath10, Jorge Mouro11, James Parker, PhD12, Huaping Tang13, Rakesh Popat, MD14, Adam D. Cohen, MD15, Daniel E. Lowther16
1 GSK, Baar Onyx, Switzerland
2 Memorial Sloan Kettering Cancer Center, New York, NY, United States
3 Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty, Heidelberg, Germany
4 GSK, Upper Providence, PA, United States
5 GSK, Upper Providence, PA, United States
6 GSK, Stevenage, United Kingdom
7 GSK, Upper Providence, PA, United States
8 GSK, Stevenage, United Kingdom
9 GSK, London, United Kingdom
10 GSK, Upper Providence, PA, United States
11 GSK, Baar Onyx, Switzerland
12 GSK, London, United Kingdom
13 GSK, Upper Providence, PA, United States
14 National Institute for Health Research University College London Hospitals Clinical Research Facility, University College London Hospitals National Health Service Foundation Trust, London, United Kingdom
15 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 GSK, Stevenage, United Kingdom

Introduction: BCMA-targeting therapies, including the antibody-drug conjugate belantamab mafodotin (belamaf), chimeric antigen receptor T-cell (CAR-T) therapies, and bispecific antibodies (BsAbs), have revolutionized MM treatment by producing overall survival benefits vs standard-of-care triplets. However, mechanisms of resistance around immune dysfunction (Vishwamitra et al. Haematologica 2026 [Epub ahead of print]) and genomic alterations (Lee et al. Nat Med 2023;29:2295–306) post BsAbs and CAR-T are becoming better characterized. Indeed, monoallelic deletions coupled with extracellular domain mutations in TNFRSF17 occur at relatively high frequencies (~50%) post anti-BCMA BsAbs (Lee et al. Nat Med 2023). In contrast, belamaf treatment has generally maintained membrane-bound and soluble BCMA (sBCMA) expression and has shown no negative impact on the immune system (Musa et al. Haematologica 2026;111:665–78). However, whether belamaf causes mutations in BCMA that may affect binding remains unknown. Understanding this would better elucidate how subsequent BCMA-targeting agents could be impacted, aiding optimization of treatment sequencing decisions. This study assessed whether single nucleotide variants (SNVs) after belamaf treatment are a mechanism of resistance, and if any SNVs affect other BCMA-targeting therapies.

Methods: For post-hoc mutational analyses, paired baseline (BL) and end-of-treatment (EoT) circulating free DNA samples from patients (pts) in the DREAMM-7 (D7) and DREAMM-8 (D8) trials, and healthy controls were sequenced using Altum EVOseq BCMA (Altum Sequencing, Madrid, Spain). The panel included 10 amplicons covering the full BCMA coding sequence, with all three possible single nucleotide substitutions assessed at each position across the amplicon sequences, leading to 1418 evaluable mutations after exclusion of synonymous and polymorphic SNVs. The detection threshold used for this BCMA panel was 10⁻³. Binding assays utilizing belantamab (the unconjugated monoclonal antibody), antigen-binding domain of BCMA-targeted CAR-T cells, and a BsAb were conducted to: (1) map BCMA-binding epitope overlap, (2) evaluate binding to wild-type and novel BCMA epitopes, and (3) measure binding to sBCMA in EoT samples from pts from D7 and D8 post-belamaf treatment (post hoc analysis).

Results: In total, paired samples from 70 pts across D7/D8 were interrogated for SNVs in TNFRSF17 (54 pts had progressive disease at EoT; 16 pts had ongoing response). Overall, 1 novel low allele frequency variant (143C>T; Ser48Leu [S48L]) was detected in an EoT sample that was not identifiable in the corresponding BL sample (1/70 [1.4%]; in a D8 pt who achieved stable disease). One additional extracellular variant (I22M) was identified in a belamaf-treated pt; this variant was identified at BL and cleared by EoT. Nonetheless, to evaluate the potential binding impact of these extracellular domain mutations (S48L and I22M), we investigated binding to belantamab, BsAbs (elranatamab, linvoseltamab, and teclistamab) and the antigen-binding domains of CAR-T therapies (ciltacabtagene autoleucel, idecabtagene vicleucel). An in-house protein-protein binding assay, based on biolayer interferometry, was developed. Its analytical validity was confirmed by its ability to successfully reproduce the previously published impact of R27P, S30del, P33S, and P34del mutations on BsAb binding (Lee et al. Nat Med 2023). We found that the S48L and I22M variants could still be bound by all tested BCMA-targeting agents, with binding affinity similar to wild-type BCMA. This was further corroborated using pt samples where binding of teclistamab, elranatamab, and linvoseltamab (utilizing electrochemiluminescence) to post-belamaf sBCMA samples was not compromised, indicating the BCMA antigen appears unaffected by prior belamaf exposure.

Conclusions: Belamaf treatment does not compromise the BCMA target, evidenced by the near absence of belamaf-induced mutations within the extracellular binding domain that may confer resistance to subsequent BCMA-targeting CAR-T cells and BsAbs. Furthermore, sustained binding of BsAbs to sBCMA post belamaf treatment supports target integrity. Collectively, these findings may have implications on sequencing of BCMA targeted therapies by demonstrating that prior belamaf exposure does not lead to BCMA SNVs, thereby preserving the binding efficacy for subsequent BCMA-directed therapies.

Daniel E. Lowther: GSK - Current equity holder in publicly-traded company; GSK - Current Employment